0.3% Ofloxacin Eye Drops 10ml | Fluoroquinolone Antibacterial Eye Solution

0.3% Ofloxacin Eye Drops 10ml: What the Published Guidance Says

Fifteen ophthalmic products spanning anti-infective, anti-allergic, anti-inflammatory, antiviral and ocular-surface categories — including the two anti-infectives the WHO Model List names for conjunctivitis and infectious keratitis.

0.3% Ofloxacin Eye Drops 10ml is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Ophthalmic range overview.

• Ofloxacin 0.3% — for keratitis, and extended to conjunctivitis Ofloxacin eye drops 0.3% are listed for infectious keratitis, and in 2021 the Expert Committee recommended expanding the indication to include conjunctivitis. Topical fluoroquinolones are the class the Committee endorsed for infectious keratitis. WHO eEML — Ofloxacin (ophthalmological)
• Trachoma and endophthalmitis have separate recommendations For trachoma the treatment of choice is a single oral dose of azithromycin, with topical azithromycin or tetracycline also indicated. For bacterial endophthalmitis, the listings for ceftazidime, ceftriaxone and vancomycin were extended to cover it as a first-choice option, with the Committee noting that intravitreal administration requires specialist training and adequate infrastructure. WHO eEML — Ofloxacin (ophthalmological)
• Gentamicin eye drops 0.3% are on the Model List for ocular infection WHO lists gentamicin eye drops 0.3% (gentamicin sulfate) for infectious blepharitis, classified in the Access group of the AWaRe framework. The Expert Committee has specified amikacin, kanamycin, netilmicin and tobramycin as therapeutic alternatives under the gentamicin square-box listing. WHO eEML — Gentamicin (ophthalmological)

Each point above is reproduced because it has a practical consequence for 0.3% Ofloxacin Eye Drops 10ml: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

How 0.3% Ofloxacin Eye Drops 10ml Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for 0.3% Ofloxacin Eye Drops 10ml follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

• Testing for description and identification
• Testing for assay of the active substance
• Testing for related substances and impurities
• Testing for dissolution or release profile (solid oral forms)
• Testing for uniformity of dosage units
• Testing for water content and pH where applicable

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How 0.3% Ofloxacin Eye Drops 10ml Is Packed, Labelled and Shipped

• Pack size: Sterile multi-dose dropper bottle (10ml) with tamper-evident seal. Non-standard pack sizes can be quoted against your artwork.
• Storage: Store at room temperature (15°C-25°C), protected from light. Keep container tightly closed. Do not freeze. Discard within 4 weeks of first opening..
• Shelf life: 24 months unopened; discard within 4 weeks of first opening. Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for 0.3% Ofloxacin Eye Drops 10ml

The legal manufacturer named on every document for 0.3% Ofloxacin Eye Drops 10ml is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

• Method validation, stability protocol and the shelf-life justification for the marketed pack.
• Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
• Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
• Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
• Batch manufacturing and packaging records released for inspection on request during supplier audits.

0.3% Ofloxacin Eye Drops 10ml is presented here against ophthalmic preparations used in WHO and MSF eye-care protocols. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.